5:45 PM
 | 
Oct 16, 2012
 |  BC Extra  |  Company News

Eisai completes German pricing negotiations for Halaven

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) reached an agreement on the price for breast cancer drug Halaven...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >